CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage with a market capitalization of $2.95 million, is progressing in its preclinical studies for an intranasal formulation of Naloxone, a medication critical for reversing opioid overdoses. According to InvestingPro data, the company’s stock currently trades at $0.70, near its 52-week low of $0.67. In collaboration with Professor Fabio Sonvico from the University of Parma, the company is evaluating its Trap and Target™ (T&T) platform’s potential to enhance the drug’s nasal delivery.
The ongoing preclinical studies will analyze various aspects of the intranasal formulation, including drug loading, release kinetics, and stability. These factors are crucial for ensuring the efficacy and safety of Naloxone when administered during an opioid overdose emergency. While the company advances its research, InvestingPro analysis reveals challenging financial metrics, including an EBITDA of -$0.65 million in the last twelve months and a weak overall Financial Health Score of 1.63.
Tomer Izraeli, CEO of Polyrizon, emphasized the urgency of addressing the opioid crisis and the company’s commitment to improving Naloxone administration. The T&T platform, according to Izraeli, may offer higher bioavailability and optimized release profiles, which are essential for rapid intervention in overdose situations.
Naloxone has been a cornerstone in the fight against the opioid epidemic, which has seen a surge in fatalities due to synthetic opioids like fentanyl. The intranasal delivery method of Naloxone presents several benefits, such as ease of use and the elimination of the need for medical professionals during administration, making it more accessible to first responders and individuals at risk.
The global market for Naloxone is projected to reach $2.47 billion by 2032, with the intranasal spray segment expected to hit $1.4 billion by 2030. As Polyrizon continues its preclinical studies, these findings could contribute to a significant portion of this growing market. Investors should note that InvestingPro has identified over 10 additional key insights about PLRZ’s financial position and market performance, available to subscribers.
Polyrizon specializes in developing hydrogel-based medical devices, including their proprietary Capture and Contain™ (C&C) technology, which functions as a biological mask by forming a barrier in the nasal cavity against viruses and allergens.
This article is based on a press release statement from Polyrizon Ltd. and contains forward-looking statements subject to risks and uncertainties. Actual results may differ materially from those projected in the forward-looking statements.
In other recent news, Polyrizon Ltd. has initiated preclinical studies for a nasal form of Naloxone, a drug commonly used to counteract opioid overdoses. This research, conducted in collaboration with Professor Fabio Sonvico from the University of Parma, aims to evaluate the efficacy of Polyrizon’s Trap and Target™ platform in enhancing the bioavailability and effectiveness of Naloxone. Additionally, Polyrizon has filed a divisional patent application in Israel to protect its Trap & Target (T&T) platform technology, which focuses on improving intranasal drug delivery. This patent filing complements a recent U.S. application covering aspects of its core technologies, including the Capture and Contain (C&C™) platform. The T&T platform is designed to increase the residence time and contact of medications with mucosal tissues, potentially transforming intranasal drug delivery. Polyrizon’s CEO, Tomer Izraeli, believes that these advancements could significantly improve the safety and efficacy of a wide range of medications. The company is also advancing its C&C hydrogel technology, which aims to provide a barrier against viruses and allergens. These developments underscore Polyrizon’s commitment to addressing healthcare challenges through innovative drug delivery solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.